Neurocloud VOL

Qubiotech

Neurocloud VOL provides volumetric analysis for atrophy and lesion quantification in MRI. It assists in the follow-up and evolution of neurodegenerative pathologies.
- MRI T1: identifies atrophy in the patient’s brain. Clinically relevant brain structures are segmented and volumetric data from the patient’s brain is compared with the normality distribution.
- FLAIR: identifies inflammatory lesions and hyperintense regions in white matter, and presents results in graphics and images for both the evolution of the atrophy and the growth/decrease of the lesions and the appearance of new lesions.
Product specifications Information source: Vendor
Last updated: Dec. 6, 2021
General
Product name Neurocloud VOL
Company Qubiotech
Subspeciality Neuro
Modality MR
Disease targeted Multiple sclerosis (MS), epilepsy, dementia, Alzheimer's Disease (AD),
Key-features Atrophy and white matter lessions identification, brain ROI segmentation, white and grey matter quantification, normative comparison, number and clasification of lesions, longitudinal analysis
Suggested use During: interactive decision support (shows abnormalities/results only on demand), During: report suggestion
Data characteristics
Population Patients with a brain 3D T1 MR from 18 to 90yo.
Input T1 and FLAIR MR (3D, non-contrast)
Input format DICOM
Output Table of quantified values, segmentation overlay, analysis by regions of interest, graphic identification of ROIs, voxel-to-voxel parametric analysis, customizable report
Output format PDF, DICOM, NIFTI, EXCEL
Technology
Integration Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 1 - 10 minutes
Certification
CE
Certified, Class I , MDD
FDA
 No or not yet
Market presence
On market since 01-2019
Distribution channels Eureka Clinical AI, Alma HEALTH PLATFORM
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model Pay-per-use, Subscription, Customizable plans
Based on Number of installations, Number of analyses, Customizable plans
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers